LEO Pharma has signed a definitive agreement for the acquisition of Replay, which focuses on treating rare genetic dermatological conditions.

Sales for Lilly blew past expectations in the quarter as demand for weight loss treatments showed no signs of abating.

Axsome Therapeutics has received FDA approval for Auvelity to treat agitation associated with dementia due to Alzheimer’s.